HUMACYTE INC (HUMA:NASDAQ)
$0.6816 -0.0196 (-2.7952%)
Analysed HUMACYTE INC (HUMA:NASDAQ) News Sources
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
27-07-2026
yahoo.com
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
12-08-2026
yahoo.com
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
12-08-2026
yahoo.com
Humacyte Q2 Earnings Call Highlights
12-08-2026
marketbeat.com
Humacyte Inc (HUMA) (Q2 2026) Earnings Call Highlights: Strong Trial Results and Strategic ...
12-08-2026
yahoo.com
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women
13-08-2026
yahoo.com
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall
13-08-2026
yahoo.com
Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds
13-08-2026
yahoo.com
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
19-08-2026
yahoo.com
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
24-08-2026
yahoo.com
What is the current price of HUMACYTE INC (HUMA:NASDAQ)?
The current price of HUMACYTE INC (HUMA:NASDAQ) is $0.6816.
HUMACYTE INC (HUMA:NASDAQ) absolute price change since previous trading day?
The absolute price change of HUMACYTE INC (HUMA:NASDAQ) since the previous trading day is $-0.0196.
HUMACYTE INC (HUMA:NASDAQ) percentage price change since previous trading day?
The percentage price change of HUMACYTE INC (HUMA:NASDAQ) since the previous trading day is -2.7952%.
What is the most recent average sentiment score for HUMACYTE INC (HUMA:NASDAQ)?
The most recent average sentiment score for HUMACYTE INC (HUMA:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for HUMACYTE INC (HUMA:NASDAQ)?
The most recent sentiment for HUMACYTE INC (HUMA:NASDAQ) is .
SEC-8K** Filing Available For HUMACYTE INC (HUMA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.